DRAXIS Obtains Final Order for Proposed A...(requirements applicable to the man...),Health

manufacture and marketing of DRAXIS' products;

- DRAXIS' ability to obtain and enforce effective patents;

- the non-infringement of third party patents or proprietary rights by

DRAXIS and its products;

- factors beyond DRAXIS' control that could cause interruptions in

operations in its single manufacturing facility (including, without

limitation, material equipment breakdowns);

- reimbursement policies related to health care;

- the establishment and maintenance of strategic collaborative and

commercial relationships;

- DRAXIS' dependence on a small number of key customers;

- the disclosure of confidential information by DRAXIS' collaborators,

employees or consultants;

- the preservation of healthy working relationships with DRAXIS' union

and employees;

- DRAXIS' ability to grow the business;

- the fluctuation of DRAXIS' financial results and exchange and interest

rate fluctuations;

- the adaptation to changing technologies;

- the loss of key personnel;

- the avoidance of product liability claims;

- the loss incurred if current lawsuits against DRAXIS succeed;

- the volatility of the price of DRAXIS' common shares;

- market acceptance of DRAXIS' products;

- factors described under "Outlook" in DRAXIS' MD&A for the most recent

quarter; and

- the risks described in "Item 3. Key Information - Risk Factors" in the

Annual Report Form 20-F filed by DRAXIS with the United States

Securities and Exchange Commission and which is also filed as DRAXIS'

Annual Information Form with Canadian securities regulators.

For additional information with respect to certain of these and other factors, and relating to DRAXIS generally, reference is made to DRAXIS' most recent filings with the United States Securities and Exch
'/>"/>